{"disease":{"id":"melanoma-braf-v600e-k-mutated","name":"melanoma braf v600e k mutated"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06784648","title":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"BioInvent International AB","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}